Abstract:PurposeNuclear factor (NF)-κB signaling in cancer cells has been reported to be involved in tumorigenesis. Phosphorylation and degradation of inhibitor of NF-κBα (IκBα) is a canonical pathway of NF-κB signaling. Here, we aimed to identify and characterize noncanonical activation of NF-κB signaling by ubiquitin-conjugating enzyme E2S (UBE2S) in lung adenocarcinoma cells.MethodsTCGA and the Human Atlas Protein Database were used to analyze the survival rate of lung adenocarcinoma patients in conjunction with UBE2S expression. In addition, PC9, H460, H441 and A549 lung adenocarcinoma cells were used in this study. PC9 and H460 cells were selected for further analysis because they expressed different UBE2S protein levels. Specific IKK inhibitors, PS1145 and SC514, were used to assess IκBα phosphorylation. Western blot analysis was used to assess protein levels in PC9 and H460 cells. A scratch wound-healing assay was used to analyze the migrative abilities of PC9 and H460 cells. Overexpression and knockdown of UBE2S in H460 and PC9 cells were used to analyze their effects on downstream protein levels. Immunoprecipitation, immunofluorescent staining, glutathione S transferase (GST) pull-down and in vitro binding assays were used to analyze the interaction between UBE2S and IκBα. A luciferase assay was used to analyze activation of NF-κB signaling regulated by UBE2S. An in vivo zebrafish xenograft model was used to assess metastasis of PC9 cells regulated by UBE2S.ResultsWe found that UBE2S expression in lung adenocarcinoma patients was negatively related to survival rate. The protein level of UBE2S was higher in PC9 cells than in H460 cells, which was opposite to that observed for IκBα. PC9 cells showed a higher UBE2S expression and migrative ability than H460 cells. Phosphorylation of IκBα was not changed by treatment with the IKK-specific inhibitors PS1145 and SC514 in PC9 and H460 cells. Overexpression and knockdown of UBE2S in H460 and PC9 cells revealed that the protein levels of IκBα were inversely regulated. Immunoprecipitation, immunofluorescent staining, GST pull-down and in vitro binding assays revealed direct binding of UBE2S with IκBα. Nuclear P65 protein levels and luciferase assays showed that NF-κB signaling was regulated by UBE2S. The expression of epithelial-to-mesenchymal (EMT) markers and the migrative ability of lung adenocarcinoma cells were also regulated by UBE2S. A zebrafish xenograft tumor model showed a reduction in the metastasis of PC9 cells that was induced by UBE2S knockdown.ConclusionsHigher UBE2S expression in lung adenocarcinomas may lead to increased binding with IκBα to activate NF-κB signaling and promote adenocarcinoma cell metastasis. UBE2S may serve as a potential therapeutic target for lung adenocarcinomas.

UBE2S is associated with malignant characteristics of breast cancer cells

UBE2S activates NF-κB signaling by binding with IκBα and promotes metastasis of lung adenocarcinoma cells

UBE2S exerts oncogenic activities in urinary bladder cancer by ubiquitinating TSC1

Ubiquitin-Binding Enzyme E2 Promotes Ovarian Cancer Cell Migratory and Proliferative Activity by Regulating EMT Induction

Ubiquitin-conjugating enzyme E2C: a potential cancer biomarker.

A Comprehensive Bioinformatics Analysis of UBE2C in Cancers

UBE2O promotes the proliferation, EMT and stemness properties of breast cancer cells through the UBE2O/AMPK2/mTORC1-MYC positive feedback loop

UBE2O promotes the proliferation, EMT and stemness properties of breast cancer cells through the UBE2O/AMPKα2/mTORC1-MYC positive feedback loop

UBE2C serves as a prognosis biomarker of uterine corpus endometrial carcinoma via promoting tumor migration and invasion

UBE2S targets RPL26 for ubiquitination and degradation to promote non-small cell lung cancer progression via regulating c-Myc

Comprehensive Investigation into the Role of Ubiquitin-Conjugating Enzyme E2S in Melanoma Development

Exceptionally high UBE2C expression is a unique phenomenon in basal-like type breast cancer and is regulated by BRCA1.

UBE3B promotes breast cancer progression by antagonizing HIF-2α degradation

UBE2C-mediated Autophagy Inhibition Via Ubiquitination of SIRT1 Contributes to Endometrial Cancer Progression.

UBE2T promotes breast cancer tumor growth by suppressing DNA replication stress

UBE2S Promotes Malignant Properties Via VHL/HIF‐1α and VHL/JAK2/STAT3 Signaling Pathways and Decreases Sensitivity to Sorafenib in Hepatocellular Carcinoma

Ube2v1-mediated ubiquitination and degradation of Sirt1 promotes metastasis of colorectal cancer by epigenetically suppressing autophagy

UBE2T Silencing Suppresses Proliferation and Induces Cell Cycle Arrest and Apoptosis in Bladder Cancer Cells.

UBE2S as a novel ubiquitinated regulator of p16 and -catenin to promote bone metastasis of prostate cancer

UBE2S as a novel ubiquitinated regulator of p16 and β-catenin to promote bone metastasis of prostate cancer

Elevated Expression of UBE2T Exhibits Oncogenic Properties in Human Prostate Cancer.